



## SUSPECTED ADVERSE DRUG REACTION REPORTING FORM

For **VOLUNTARY** reporting of ADRs by Healthcare Professionals

**INDIAN PHARMACOPOEIA COMMISSION** (National Coordination Centre-Pharmacovigilance Programme of India)

Ministry of Health & Family Welfare, Government of India, Sector-23, Raj Nagar, Ghaziabad-201002

**PvPI Helpline (Toll Free) :1800-180-3024** (9:00 AM to 5:30 PM, Monday-Friday)

Initial Case <input type="checkbox"/>		Follow-up Case <input type="checkbox"/>		FOR AMC / NCC USE ONLY							
<b>A. PATIENT INFORMATION *</b>				<b>Reg. No. / IPD No. / OPD No. / CR No. :</b>							
1. Patient Initials:		2. Age or date of birth:		<b>AMC Report No. :</b>							
3. Gender: M <input type="checkbox"/> F <input type="checkbox"/> Other <input type="checkbox"/>		4. Weight (in Kg.)		<b>Worldwide Unique No. :</b>							
<b>B. SUSPECTED ADVERSE REACTION *</b>				12. Relevant investigations with dates :							
5. Event / Reaction start date (dd/mm/yyyy)				13. Relevant medical / medication history (e.g. allergies, pregnancy, addiction, hepatic, renal dysfunction etc.)							
6. Event / Reaction stop date (dd/mm/yyyy)											
7. Describe Event/Reaction management with details , if any											
<b>C. SUSPECTED MEDICATION(S) *</b>				14. Seriousness of the reaction : No <input type="checkbox"/> if Yes <input type="checkbox"/> (please tick anyone)							
				<input type="checkbox"/> Death (dd/mm/yyyy) <input type="checkbox"/> Congenital-anomaly <input type="checkbox"/> Life threatening <input type="checkbox"/> Disability <input type="checkbox"/> Hospitalization-Initial/Prolonged <input type="checkbox"/> Other Medically important							
				15. Outcome:							
				<input type="checkbox"/> Recovered <input type="checkbox"/> Recovering <input type="checkbox"/> Not Recovered <input type="checkbox"/> Fatal <input type="checkbox"/> Recovered with sequelae <input type="checkbox"/> Unknown							
<b>S. No.</b>											
<b>8. Name (Brand/ Generic)</b>											
<b>Manufacturer (if known)</b>											
<b>Batch No. / Lot No.</b>											
<b>Expiry Date (if known)</b>											
<b>Dose</b>											
<b>Route</b>											
<b>Frequency</b>											
<b>Therapy Dates</b>											
<b>Date Started</b>											
<b>Date Stopped</b>											
<b>Indication</b>											
<b>Causality Assessment</b>											
<b>i</b>											
<b>ii</b>											
<b>iii</b>											
<b>Iv<sup>#</sup></b>											
9. Action taken after reaction (please tick)								10. Reaction reappeared after reintroduction of suspected medication (please tick)			
<b>S. No. as per C</b>											
<b>Drug withdrawn</b>											
<b>Dose increased</b>											
<b>Dose reduced</b>											
<b>Dose not changed</b>											
<b>Not applicable</b>											
<b>Unknown</b>											
<b>Yes</b>											
<b>No</b>											
<b>Effect unknown</b>											
<b>Dose (if re-introduced)</b>											
<b>i</b>											
<b>ii</b>											
<b>iii</b>											
<b>iv</b>											
11. Concomitant medical product including self-medication add herbal remedies with therapy dates (Exclude those used to treat reaction)											
<b>S. No.</b>											
<b>Name (Brand / Generic)</b>											
<b>Dose</b>											
<b>Route</b>											
<b>Frequency (OD, BD, etc.)</b>											
<b>Therapy Dates</b>											
<b>Date Started</b>											
<b>Date Stopped</b>											
<b>Indication</b>											
<b>i</b>											
<b>ii</b>											
<b>iii<sup>#</sup></b>											
<b>Additional Information :</b>				<b>D. REPORTER DETAILS *</b>							
				16. Name & Address : _____							
				Pin : _____ Email : _____							
				Contact No- : _____							
				Occupation : _____ Signature : _____							
				17. Date of this report (dd/mm/yyyy) :							
Signature and Name of Receiving Personnel :											
<b>Confidentiality : The patient's identity is held in strict confidence and protected to the fullest extent. Submission of a report does not constitute an admission that medical personnel or manufacturer or the product caused or contributed to the reaction. Submission of an ADR report does not have any legal implication on the reporter.</b>											

# Use separate page for more information

\* Mandatory Fields for suspected ADR Reporting Form

## ADVICE ABOUT REPORTING

### A. What to report?

#### All adverse events should be reported

Report non-serious, known or unknown, frequent or rare adverse drug reactions due to Medicines, Vaccines & Herbal Products.

Report every serious adverse drug reactions. A reaction is serious when the patient outcome is :

- Death
- Life-threatening
- Hospitalization (initial or prolonged)
- Disability (significant, persistent or permanent)
- Congenital anomaly
- Report intervention to prevent permanent impairment or damage

**NOTE : Serious/Adverse Event following immunization can also be reported in Serious AEFI case Notification Form available on <http://www.ipc.gov.in>**

### B. Who can report?

All healthcare professionals (Clinicians, Dentists, Pharmacists and Nurse etc.) can report adverse drug reactions

### C. Where to report?

Duty filled in Suspected Adverse Drug Reaction Reporting Form can be sent to the nearest Adverse Drug Reaction Monitoring Centre (AMC) or directly to the National Coordination Centre (NCC) for PvPI.

**Call on Helpline (Toll Free) 1800 180 3024** to report ADRs or directly mail this filled form to [pvpi.ipc@gov.in](mailto:pvpi.ipc@gov.in)

A list of nationwide AMCs is available at : <http://www.ipc.gov.in>, [http://www.ipc.gov.in/PvPI/pv\\_home.html](http://www.ipc.gov.in/PvPI/pv_home.html)

### D. What happens to the submitted information?

- Information provided in this form is handled in strict confidence. The causality assessment is carried out at AMCs by using WHO-UMC scale. The analyzed forms are forwarded to the NCC-PvPI through ADR database. Finally the data is analyzed and forwarded to the Global Pharmacovigilance Database managed by WHO Uppsala Monitoring Centre in Sweden.
- The reports are periodically reviewed by the NCC-PvPI. The information generated on the basis of these reports helps in continuous assessment of the benefit-risk ratio of medicines.
- The Signal Review Panel of PvPI reviews the data and suggests any interventions that may be required.

### E. Mandatory fields for suspected ADR Reporting Form (\*)

Patient initials, age at onset of reaction, reaction term(s), date of onset of reaction, suspected medication(s) & reporter information.

#### For Adverse Drug Reaction Reporting Tools

- E-mail : [pvpi.ipc@gov.in](mailto:pvpi.ipc@gov.in)
- PvPI Helpline (Toll Free) : 1800 180 3024 (9:00 AM to 5:30 PM, Monday-Friday)
- ADR Mobile App : "ADRPvPI"